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Abstract
Background: Solar elastosis and neval remnants are histologic markers characteristic of divergent melanoma pathways 
linked to differences in age at onset, host phenotype, and sun exposure. However, the association between these pathway 
markers and newly identified low-penetrance melanoma susceptibility loci remains unknown.
Methods: In the Genes, Environment and Melanoma (GEM) Study, 2103 Caucasian participants had first primary melanomas 
that underwent centralized pathology review. For 47 single-nucleotide polymorphisms (SNPs) previously identified as low-
penetrant melanoma risk variants, we used multinomial logistic regression to compare melanoma with solar elastosis and 
melanoma with neval remnants simultaneously to melanoma with neither of these markers, excluding melanomas with 
both markers. All statistical tests were two-sided.
Results: IRF4 rs12203592 was the only SNP to pass the false discovery threshold in baseline models adjusted for age, sex, 
and study center. rs12203592*T was associated positively with melanoma with solar elastosis (odds ratio [OR] = 1.47, 95% 
confidence interval [CI] = 1.18 to 1.82) and inversely with melanoma with neval remnants (OR = 0.65, 95% CI = 0.48 to 0.87) 
compared with melanoma with neither marker (Pglobal = 3.78 x 10
-08). Adjusting for phenotypic characteristics and total sun 
exposure hours did not materially affect rs12203592’s associations. Distinct early- and late-onset age distributions were 
observed in patients with IRF4 rs12203592 [CC] and [TT] genotypes, respectively.
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Conclusions: Our findings suggest a role of IRF4 rs12203592 in pathway-specific risk for melanoma development. We 
hypothesize that IRF4 rs12203592 could underlie in part the bimodal age distribution reported for melanoma and linked to 
the divergent pathways.
Melanoma incidence has increased in fair-skinned populations 
worldwide in recent decades (1,2). Understanding melanoma 
etiology is critical for prevention; however, risk factors may 
differ by the pathway along which melanoma develops. The 
divergent pathway hypothesis postulates at least two separate 
pathways, one related to chronic sun exposure and the other 
related to the host’s tendency to develop nevi, with melano-
mas marked, respectively, by the presence of histologic solar 
elastosis (SE) and neval remnants (NR) in adjacent tissue (3–5). 
Predictors of SE and NR adjacent to melanomas include host 
phenotypic characteristics; however, the association of these 
pathway markers with recently identified germline variants in 
melanoma-associated risk loci has yet to be explored (5–7).
The divergent pathway model postulates that melanoma 
risk associated with UV exposure differs by host characteristics 
and results in at least two causal pathways linked to differences 
in age at onset, body site, and histopathologic features (4,5,8). 
In individuals with low propensity to develop nevi, melanomas 
seem to require high levels of cumulative sun exposure (4,9). 
These chronic sun exposure–related melanomas, marked by 
SE, tend to occur at older ages, in individuals with fewer nevi, 
and on sun exposed body sites like the head/neck (3,5,9,10). 
Conversely, melanomas in individuals with a high propensity 
to develop nevi seem to require lower levels of sun exposure 
and arise from an existing nevus (4). These nevogenic melano-
mas, marked by NR, tend to occur at younger ages, in individuals 
with higher nevus counts, and on less sun-exposed sites like the 
trunk (11–15).
Recent genome wide association studies (GWAS) and can-
didate pathway studies have identified several low-penetrant 
genetic variants associated with cutaneous melanoma (16). The 
majority are in loci associated with pigmentation (eg, TYRP1, 
TYR, HERC2/OCA2, SLC45A2, and ASIP), nevi (eg, PLA2G6, MTAP, 
and NID1), or both (eg, IRF4) (17–24); however, variants in other 
identified loci (eg, ATM, MX2, PARP1, ARNT, and CASP8) may not 
be associated with phenotypic risk traits for melanoma (21,25).
Within the large international population-based Genes, 
Environment, and Melanoma (GEM) Study, we previously inves-
tigated 47 single-nucleotide polymorphisms (SNPs) in 21 of 
these putative low-penetrance melanoma susceptibility loci and 
found variants in the TERT, TYRP1, MTAP, TYR, NCOA6, and MX2 
gene regions and a PARP1 haplotype to be associated with mul-
tiple primary melanoma compared with single primary mela-
noma (26). The purpose of this study was to determine whether 
these 47 SNPs influence susceptibility to melanomas arising 
from the chronic sun exposure or nevogenic pathways by exam-
ining their associations with the exclusive presence of SE or NR 
adjacent to primary melanoma.
Methods
Study Population
The population-based case-only GEM Study enrolled 3579 
patients diagnosed between 1998 and 2003 with incident pri-
mary melanoma in Australia, Canada, Italy, and the United 
States (27,28). Of the 2953 (83% of 3567) Caucasian patients with 
centralized pathology review, 2103 (86% of 2458) were diagnosed 
with a first primary melanoma and are included in the analyses 
reported here. The institutional review boards of participating 
institutions approved the protocol, and informed consent was 
obtained from participants.
Hair and eye color, ability to tan, number of back nevi, resi-
dential histories, and sun exposure information were collected 
from phone interviews and self-administered questionnaires as 
described previously (9,29,30). Number of back nevi is statisti-
cally significantly correlated with whole-body nevus density 
diagrams (31) in GEM, and the suitability of using this variable 
as a proxy for total body nevus counts has been previously 
reported (32–34). Total hours of sun exposure from the age of 
five years until the age at diagnosis were calculated as the sum 
of reported outdoor sun exposure hours between 9 am and 5 pm 
on working and nonworking days in warmer and cooler months 
(based on residential calendars) estimated for each decade of 
life (29). Average annual sun exposure was calculated as the 
total exposure hours divided by the participant’s age at diagno-
sis minus five years (29).
Three dermatopathologists scored adjacent SE as previously 
described (9) and adjacent NR as present when benign nevus 
cells were in the epidermis or dermis immediately adjacent to or 
below the melanoma cells. Kappa statistics, using the three cat-
egories, were 0.60 and 0.64 for scoring NR and SE, respectively, in 
a test set of 19 H&Es reviewed by the three dermatopathologists.
SNP Selection, Genotyping, and Principal Component 
Analysis
We selected 47 SNPs from 21 loci based on evidence they were 
low-penetrant risk variants for melanoma in other studies (26). 
DNA was collected from buccal swabs. SNPs were genotyped 
using the MassArray iPLEX chemistry and platform (Agena 
Bioscience), with quality control measures as described previ-
ously (35). Proxy SNPs (r2 > 0.95; 1000 Genomes, CEU population; 
Proxy SNP; Broad Institute) rs6735656 and rs12278954 were sub-
stituted, respectively, for CASP8 rs10931936 and ATM rs1801516 
(21)—two SNPs of interest rejected during the assay design steps.
We performed principal component analysis (PCA) of the 47 
SNPs with and without MC1R (available to this dataset [36,37]) to 
detect potential population structure within our data. Using an 
eigen-value decomposition approach, we transformed and pro-
jected our data into lower dimensional spaces by extracting the 
top principal components (PCs) that explain most of the total 
variance.
Statistical Analyses
A joint outcome variable was created with three levels: melano-
mas with SE+/NR- (adjacent SE but not NR), SE-/NR+ (adjacent 
NR but not SE), or SE-/NR- (neither SE nor NR). Melanomas with 
SE+/NR+ (adjacent SE and NR) were excluded because our goal 
was to determine the associations of genetic variants separately 
for melanomas with one marker or the other. Multinomial logis-
tic regression was used to estimate the per-allele odds ratios 
(ORs) and 95% confidence intervals (CIs) of each SNP for SE+/
NR- and SE-/NR+ melanomas compared simultaneously with 
SE-/NR- melanomas. Initial models used an additive model of 
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inheritance of the minor allele of each SNP and were adjusted 
for baseline features: age (tertiles), sex, and study center. The 
false discovery threshold adjusted for multiple comparisons 
was computed using a resampling method that takes into 
account the linkage disequilibrium information among SNPs 
evaluated (38,39).
For the one SNP that passed false discovery (IRF4 rs12203592), 
different models of inheritance were compared using the Akaike 
information criterion statistic corrected for the number of model 
parameters (AICc). We selected the model with the lowest value 
indicating superior fit of the data (40). Next, the associations of 
IRF4 rs12203592 with phenotypic characteristics were estimated 
using multinomial logistic regression models adjusted for base-
line features and limited to patients with no missing phenotypic 
data. We then estimated the associations of rs12203592, each 
phenotypic characteristic, and total sun exposure hours with 
SE+/NR- and SE-/NR+ melanomas compared simultaneously 
with SE-/NR- melanomas in separate baseline-adjusted models 
limited to patients with no missing data for rs12203592, pheno-
type, or sun exposure hours. The associations of each variable 
with SE+/NR- and SE-/NR+ melanomas were then estimated in 
a multivariable model.
Age density distributions were plotted by the presence/
absence of SE/NR and by the IRF4 rs12205932 genotype using R, 
version 3.2.0 (R package ‘sm’: nonparametric smoothing meth-
ods, version 2.2–5.4). All other statistical analyses were per-
formed in SAS (SAS Institute, Cary NC) version 9.4. The Wilcoxon 
rank-sum test was used to compare the median patient age at 
onset of melanomas with SE+/NR- and SE-/NR+ melanomas, 
each relative to SE-/NR- melanomas. All tests of statistical sig-
nificance were two-sided, with a threshold of .05.
Results
Of the 2103 Caucasian patients in GEM with centrally reviewed 
incident first primary melanomas, the median age was 55 years 
and 51.7% were male (Table 1). Data for SE were available for 
2048 (97.4% of 2103) and NR for 2090 (99.4% of 2103) of the mela-
nomas, with missing data mainly a result of insufficient sur-
rounding dermal/stromal tissue to score SE and NR. Data for 
both SE and NR were available for 2039 (97.0% of 2103) patients, 
of whom 285 (13.6% of 2103) had both SE and NR present adja-
cent to their melanoma and were excluded in the analyses, as 
our primary goal was to investigate the SE and NR pathways 
separately. SNP locations, GEM minor allele frequencies (MAF) 
overall and by study center, MAF from Hapmap CEU or pilot 
CEU, and RegulomeDB (42)-predicted functional impact are in 
Supplementary Table 1 (available online). The SNP associations 
were adjusted for center to account for possible MAF differ-
ences among the study centers. To further evaluate potential 
confounding by genetic ancestry, we performed PCA of the 47 
SNPs with and without MC1R to detect population structure. 
Scatterplots for PC1 and PC2 with study center color coded 
are shown in Supplementary Figure  1 (available online). We 
observed similar PCA loadings for participants in different 
study centers. The first three principal components were not 
statistically significantly associated with either solar elastosis 
or neval remnants and thus did not show evidence of potential 
confounding by population structure.
The associations using an additive model of inheritance of 
the 47 SNPs genotyped with SE+/NR- and SE-/NR+ relative to 
SE-/NR- melanoma are presented in Figure 1 and Supplementary 
Table 2 (available online). IRF4 rs12203592 was the only SNP to 
pass the false discovery threshold (P  =  .002). rs12203592 was 
positively associated with SE+/NR- (OR  =  1.47, 95% CI  =  1.18 
to 1.82) and inversely associated with SE-/NR+ (OR = 0.65, 95% 
CI  =  0.48 to 0.87) melanomas (Pglobal  =  3.78 x 10
-08). Comparing 
other models of inheritance for rs12203592, we found that the 
additive model had the lowest AICc value indicating the best 
fit of the data (data not shown). IRF4 rs12203592*T was statisti-
cally significantly associated (P < .05) with having 10 or fewer 
back nevi, dark hair color, light eye color, and decreased abil-
ity to tan in multinomial models adjusted for baseline features 
(Supplementary Table 3, available online).
The associations of IRF4 rs12203592, phenotypic characteris-
tics, and total sun exposure hours with SE+/NR- and SE-/NR+ rel-
ative to SE-/NR- melanoma in baseline and multivariable models 
limited to participants with complete data are shown in Table 2. 
rs12203592*T, older age, increased total sun exposure hours, 10 
or fewer back nevi, and light eye color were each statistically 
Table  1. Clinical characteristics among patients with first primary 
melanomas that underwent centralized pathology review in the GEM 
Study (n = 2103)*
Characteristic No. (%)
Age at diagnosis, y
 Median (IQR) 55 (25)
Sex
 Male 1087 (51.7)
 Female 1016 (48.3)
Solar elastosis
 Absent 720 (34.2)
 Present 1328 (63.2)
 Missing 55 (2.6)
Neval remnants
 Absent 1523 (72.4)
 Present 567 (27.0)
 Missing 13 (0.6)
Solar elastosis/neval remnants
 SE-/NR- 444 (21.1)
 SE+/NR- 1037 (49.3)
 SE-/NR+ 273 (13.0)
 SE+/NR+ 285 (13.6)
 Missing 64 (3.0)
No. of back nevi
 0–10 1186 (56.4)
 >10 883 (42.0)
 Missing 34 (1.6)
Hair color
 Dark hair (dark brown, black) 643 (30.6)
 Light hair (light brown, blonde) 1251 (59.5)
 Red 186 (8.8)
 Missing 23 (1.1)
Eye color
 Dark eyes (brown, black) 405 (19.3)
 Light eyes (blue, gray, green, hazel) 1678 (79.8)
 Missing 20 (1.0)
Ability to tan
 Deep/moderate tan 1213 (57.7)
 Mild/no tan 840 (39.9)
 Missing 50 (2.4)
* Non-Caucasians with single primary melanoma that underwent pathol-
ogy review (n = 7) were excluded. GEM = Genes, Environment and Melanoma; 
IQR = interquartile range; NR = neval remnants; SE = solar elastosis; SE+/
NR- = melanomas with solar elastosis but without neval remnants; SE-/
NR+ = melanomas with neval remnants but without solar elastosis; SE-/
NR- = melanomas without solar elastosis or neval remnants; SE+/NR+ = mela-
nomas with solar elastosis and neval remnants.
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significantly associated (P < .05) with SE+/NR- compared with 
SE-/NR- melanomas in baseline and multivariable models. Only 
rs12203592*C was statistically significantly associated (P < .05) 
with SE-/NR+ melanomas compared with SE-/NR- melanomas 
in baseline and multivariable models. Adjusting for phenotypic 
characteristics and total sun exposure hours did not materi-
ally affect rs12203592’s association with SE+/NR- or SE-/NR+ 
melanomas relative to SE-/NR- melanomas. Re-analyses were 
Figure 1. Associations of single-nucleotide polymorphisms (SNPs) with histologic solar elastosis and neval remnants adjacent to first primary melanomas in the 
Genes, Environment and Melanoma Study (n = 1754). A) Association of SNPs with melanomas with adjacent solar elastosis but without neval remnants (SE+/NR-). B) 
Association of SNPs with melanomas with adjacent neval remnants but without solar elastosis (SE-/NR+). Per-allele odds ratios (ORs), color coded by chromosome, 
and 95% confidence intervals (CIs) were estimated using multinomial logistic regression models comparing melanomas with SE-/NR+ and SE+/NR- simultaneously to 
melanomas with neither marker (SE-/NR-). Excluded were melanomas with both markers (SE+/NR+). All models were adjusted for age (tertiles), sex, and study center 
(Supplementary Table 2, available online). All statistical tests were two-sided. Square markers and * denote IRF4 rs12205392—the only SNP to pass false discovery for 
its association with SE+/NR- and SE-/NR+ melanomas compared with melanomas with neither marker (Pglobal = 3.78 x 10
-08) (ORs and 95% CIs provided in the figure). 
CI = confidence interval; OR = odds ratio.
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performed of the fully adjusted model, adding either self-
reported ancestry, log Breslow, or American Joint Committee on 
Cancer (AJCC) tumor stage (43), or substituting average annual 
total sun exposure hours for total exposure hours, but none 
of these changes materially affected rs12203592’s associations 
(results not shown).
Using all cases, including those with SE+/NR+ tumors, prob-
ability density functions revealed a bimodal distribution for age 
at diagnosis with an early-onset peak around age 50 years and 
a late-onset peak around age 75 years (Figure 2A). Age density 
plots stratified by the presence/absence of SE/NR revealed SE+/
NR- melanomas to have a predominantly late-onset distribu-
tion, SE-/NR- or SE-/NR+ melanomas to have an early-onset dis-
tribution, and SE+/NR+ melanomas to have a distribution falling 
between the early- and late-onset density peaks (Figure 2B). The 
median age at onset for SE+/NR- melanomas was statistically 
significantly higher than SE-/NR- melanomas while the median 
age at onset of SE-/NR+ and SE-/NR- melanomas did not statisti-
cally significantly differ (Table 2).
Patients with the IRF4 rs12203592 (CC) genotype had a 
predominantly early-onset distribution, peaking around age 
45 years, while patients with the (TT) genotype had a predomi-
nantly late-onset distribution, peaking around age 75  years. 
Patients with the rs12203592 (CT) genotype had a bimodal age 
distribution, with approximately equal density peaks around 
ages 50 and 70 years (Figure 2C). The age distributions differed 
by the rs12203592 genotype, even when stratified by Australia 
and North America (data not shown).
Discussion
IRF4 encodes interferon regulatory factor-4, a transcription factor 
involved in B- and T-cell development, pigmentation, and poten-
tially melanocyte differentiation and proliferation (44–47). IRF4 
(also known as MUM1) is predominantly expressed in immune 
cells but is also present in melanocytes, nevi, and primary mela-
nomas (44–47). The variant T allele of rs12203592, in intron 4 of 
IRF4, is a functional SNP shown to increase IRF4 promoter activ-
ity in Burkitt Lymphoma B-cells and repress promoter activ-
ity in human epidermal melanocytes and thus may increase 
or decrease IRF4 expression in different contexts (45,48,49). In 
mouse melanocytes, decreased expression of IRF4 as a result of 
rs12203592*T also led to decreased levels of certain downstream 
effectors of IRF4, such as the melanin-synthesizing enzyme TYR 
(45). Also, RegulomeDB (42) predicts that IRF4 rs12203592 is likely 
to affect binding.
We found that IRF4 rs12203592*T was strongly associated 
with light eye color, poor tanning ability, dark hair color, and 
lower nevus counts, consistent with previous epidemiological 
studies (18,50–52). Decreased TYR expression in melanocytic 
cells as a result of rs12203592*T might explain, at least in part, 
its association with certain fair-pigmentary traits. Adjusting for 
pigmentary traits and nevi, however, did not materially change 
the odds ratio for the association of rs12203592 with the exclu-
sive presence of SE or NR adjacent to melanomas. This suggests 
that rs12203592 could influence the development of divergent 
melanoma pathways independent of host phenotypic traits 
associated with melanoma risk. Experimental studies are 
needed to elucidate this influence, which may be linked to dif-
ferences in expression of IRF4 and its downstream targets, regu-
lated in part by the rs12203592 genotype in melanocytes and/or 
immune system cells.
IRF4 rs12203592’s association with histologic SE and NR adja-
cent to melanomas, representing divergent causal pathways, 
may also explain why this variant has been inconsistently asso-
ciated with melanoma risk in recent epidemiological studies. In 
a combined analysis of Australian, UK, and Swedish subjects, 
rs12203592*C was positively associated with melanoma, most 
statistically significantly with melanoma on the trunk (50). 
Similarly, in a UK study rs12203592*T was inversely associated 
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Figure 2. Age distributions of patients with first primary melanomas scored for 
both solar elastosis (SE) and neval remnants (NR) in the Genes, Environment and 
Melanoma Study (n = 2103) shown for (A) all cases, (B) histologic markers of diver-
gent melanoma pathways, and (C) IRF4 rs12203592 genotype. The y-axis shows 
the smoothed density estimate of the proportion of patients who were diagnosed 
with melanoma at a given age plotted in years on the x-axis. GEM = Genes, Envi-
ronment and Melanoma; SE+/NR- = melanomas with solar elastosis but without 
neval remnants; SE-/NR+ = melanomas with neval remnants but without solar 
elastosis; SE-/NR- = melanomas without solar elastosis or neval remnants; SE+/
NR+ = melanoma with solar elastosis and neval remnants.
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with melanoma, most statistically significantly with melanoma 
on the trunk (53). In contrast, rs12203592*T was positively asso-
ciated with melanoma risk in two US studies (52,54). In another 
Australian study, rs12203592*T was inversely associated with 
melanoma in children/adolescents but was not associated with 
melanoma in adults (55). Further, rs12203592 was not statisti-
cally significantly associated with melanoma in a combined 
analysis of GenoMEL data with patients from Europe and Israel 
(21), nor was it associated with multiple compared with single 
primary melanoma in a recent GEM study (26). The differing 
associations in these studies may depend upon the proportion 
of melanomas that arose via the chronic sun exposure vs nevo-
genic pathway, given rs12203592’s strong and opposing asso-
ciation with the exclusive presence of SE and NR found in the 
present study.
We are not aware of another study that has reported asso-
ciations of IRF4 rs12203592 with SE or NR adjacent to melano-
mas. Previous GEM investigations and independent studies have 
found older age, fewer nevi, and higher self-reported sun expo-
sure hours to be associated with SE, with odds ratios in direc-
tions consistent with those reported here (3,5,9).
We also found a bimodal age distribution in GEM with dis-
tinct early- and late-onset peaks consistent with those reported 
previously for melanoma and which have been linked to the 
divergent causal pathways (56,57). This bimodal distribution 
has been described as displaying an early-onset peak fre-
quency for trunk melanomas and a late-onset peak frequency 
for face/ear melanomas using Surveillance, Epidemiology, and 
End Results (SEER) data (56). In GEM, melanomas without his-
tologic SE displayed an early-onset distribution similar to that 
found in SEER for trunk melanomas while melanomas without 
histologic NR but with SE had a late-onset distribution simi-
lar to that found in SEER for face/ear melanomas (56). A simi-
lar early-onset distribution was also observed in patients with 
the IRF4 rs12203592 (CC) genotype, while a similar late-onset 
distribution was observed in patients with the rs12203592 (TT) 
genotype. This suggests that the rs12203592 genotype could be 
an inherited characteristic that, in part, underlies the bimodal 
age distribution of melanomas related to divergent causal path-
ways linked to differences in age at onset, body site, and histo-
pathologic features. Further work could be done to investigate 
this possibility.
Major advantages of our study are its large sample size, 
population-based ascertainment, and centralized pathol-
ogy review. The majority of GEM participants (70%) reported 
Northern European ancestry, and the remaining persons 
divided by center into Southern European and other groups. 
While population stratification could have been an issue, the 
PCA results did not show evidence of a population substruc-
ture confounding effect. We adjusted for study center in our 
analysis, and further adjustment for self-reported ances-
try had little effect on the associations in the fully adjusted 
model. Melanomas with NR have also been reported as hav-
ing lower Breslow thickness (13,15), possibly because thicker 
melanomas overgrow and obscure any NR; however, adding log 
Breslow or AJCC tumor stage to the fully adjusted multivari-
able model did not change the ORs for rs12203592. The effect 
of age on cumulative sun exposure was of potential concern, 
but substituting average annual total sun exposure hours for 
total exposure hours did not materially affect rs12203592’s 
associations. Another limitation could be bias in the selection 
of cases for pathology review; however, none of the predic-
tor variables used in the fully adjusted multivariable model 
were associated with missing vs nonmissing pathology review. 
Also, we recognize that our SE and NR measures must contain 
some misclassification as evidenced by the modest agreement 
between our pathologists, but misclassification typically has 
the effect of attenuating observed associations. Power may 
also have been insufficient to detect associations of SNPs with 
lower MAFs (eg, SNPs in SLC45A2) in GEM. Lastly, the age dis-
tributions presented could potentially be affected by age struc-
ture and secular trends for sun exposure among the different 
populations; however, the age distributions among the GEM 
populations are quite similar, and the age distributions shifted 
by the rs12203592 genotype, even when stratified by Australia 
and North America.
IRF4 rs12203592’s independent yet contrasting associations 
with SE+/NR- and SE-/NR+ melanoma suggest that this inher-
ited genetic variant may play a pivotal role underlying suscep-
tibility to divergent pathways in melanoma development. We 
are not aware of a similar strong germline genetic crossover 
effect for another cancer with an inverse association with one 
subtype and positive association with another subtype of can-
cer. Knowledge of the genetic etiology of divergent melanoma 
pathways with resultant differences in host characteristics and 
tumor features among melanoma patients could inform future 
risk models and prevention efforts for this complex and hetero-
geneous disease.
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